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Summary
introduction: after the consensus conference in st. gallen and updated nccn guidelines, we started doing sentinel 
lymph node biopsy (slnB) in May 2017, for breast cancer patients who achieve clinical axillary remission following neoad-
juvant treatment. this study’s primary goal was to evaluate the clinical impact of slnB after neoadjuvant therapy in the 
group mentioned above.
Methods: We retrospectively analyzed all neoadjuvant breast cancer patients from May 2016 until May 2018 at clinical 
Hospital center rijeka. our preliminary results recorded the appearance of locoregional and distant recurrence.
results: from 65 patients involved in this analysis, 48 patients were node-positive at the time of diagnosis, and 45.83% 
among those achieved complete pathological axillary remission. After the first postoperative year, there were no locore-
gional relapses nor statistically significant differences in the prevalence of distant recurrences, regardless of the extent of 
surgical procedure. However, results showed higher rates of locoregional and distant relapse for the group of patients that 
did not attain complete axillary remission.
conclusion: slnB is a reliable alternative to alnD for locoregional and overall disease control for breast cancer pa-
tients who achieve complete clinical axillary remission after preoperative systemic treatment. the clinical axillary lymph 
node status, after neoadjuvant therapy, is a more relevant prognostic factor than the clinical axillary lymph node status at 
the beginning of the treatment.
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INTRODUCTION
the idea of sentinel lymph node biopsy is 
present in literature data from 1951 (1). although 
trials from the late seventies confirmed that there 
is no survival benefit from axillary lymph node 
dissection (alnD) in early-stage breast cancer pa-
tients with clinically negative axilla (2), merely at 
the end of the last century the concept of intraop-
erative detection and biopsy of sentinel lymph 
node was eventually accepted in the breast cancer 
surgery (3,4). in a short period, sentinel lymph 
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node biopsy (slnB) became the gold standard of 
axillary management for early-stage breast cancer 
(5-9).
initially contraindicated after neoadjuvant 
systemic treatment (nast), slnB has been re-
cently accepted as a reliable option in this setting, 
even for those patients with clinically involved ax-
illa before nast that shifts to clinically negative 
after treatment (10-17). in clinical Hospital center 
(cHc) rijeka, slnB was introduced as standard 
care for early-stage breast cancer since 2003, and 
from May 2017, we used the procedure for all pa-
tients after nast, who met the criteria.
PATIENTS AND METHODS
this retrospective analysis captures all fe-
male breast cancer patients (20 to 80 years old), 
surgically treated after nast in cHc rijeka (from 
May 2016 until May 2018; one year before and one 
year after slnB after nast entered the clinical 
practice). We recorded the prevalence of locore-
gional and distant recurrences after the first post-
operative year.
exclusion criteria for the analysis were pa-
tients with a history of bilateral, inflammatory, or 
t4 stage breast cancer, and M1 stage at the time of 
the diagnosis. We analyzed the data from the inte-
grated electronical records of cHc rijeka with the 
approval of the Ethics Committee of Clinical Hos-
pital center rijeka. the protocol of this trial was 
registered and publicly available at www.clinical-
trials.gov, iD: nct03833960
for statistical calculations, we used the on-
line statistical analysis software Medcalc.net. We 
considered results statistically significant when 
p = 0.05.
Clinical criteria defined metastatic axillary 
involvement: ultrasound and/or magnetic and/or 
clinically suspected and/or cytologically proven 
positive axillary lymph node(s).
the regional recurrence is the postoperative 
appearance of the disease in the unilateral axil-
lary, supraclavicular and internal mammary 
lymph nodes, local recurrence is the postoperative 
appearance of the disease in the unilateral or con-
tralateral breast or thoracic wall, and the distant 
recurrence as postoperative clinical or radiologic 
evidence of disease present anywhere else in the 
body. the progression-free survival is the absence 
of proof of locoregional and distant recurrence or 
cancer-related death in the postoperative one-year 
follow-up period.
standard nast, according to ac-t protocol, 
joined with Her-2 blockage for Her-2 enriched 
tumors, was followed by surgical procedure. 
Whether axillary treatment was alnD or slnB 
depended on the patient’s multidisciplinary reas-
sessment after nast and the date of surgery (be-
fore or after May 2017).
the basis of sentinel lymph node(s) detection 
was lymphoscintigraphy with 99mtc-labeled 
nano colloid (nanocoll®). on the day of the sur-
gery, radiocolloid was injected intradermally in 
the breast, and preoperative plane scintigraphy 
was performed after 30 minutes. We use an intra-
operative handheld gamma detecting probe (neo-
probe® gamma Detecting system)to detect senti-
nel node(s).
all nodes with the activity detected intraop-
eratively, as well as all clinically suspected lymph 
nodes (up to 6 nodes), were considered for senti-
nel nodes and were removed. if more than six 
nodes removed, it was considered an alnD.
all removed sentinel lymph nodes were in-
traoperative longitudinally transected on 4 mm 
cuts and analyzed by imprint cytology. for all 
positive or suspected cases, cuts are frozen and 
histologically examined for the presence or ab-
sence of metastasis. sentinel lymph nodes nega-
tive on imprint cytology were transected after-
ward for hematoxylin and eosin and pan-cytoker-
atin staining. therefore, detection of every 
residual tumor in the lymph node, including iso-
lated tumor cells (itc), was ensured.
to stage the primary tumor and lymph 
nodes, we used the 4th edition of WHo tnM clas-
sification form 2012 and appendix of AJCC manu-
al for breast cancer staging.
the primary goal of this analysis was to es-
tablish the prevalence of early regional, local and 
distant recurrence rates in a group of breast cancer 
patients that achieve complete axillary remission 
after nast in correlation with the extension of 
surgical procedure in the axilla (alnD vs. slnB). 
thereby, we evaluated whether slnB after nast 
is a reliable procedure for maintaining the locore-
gional and overall control of disease in the pa-
tients mentioned above. secondary endpoints of 
this analysis were the comparison of progression-
free survival rates among a group of patients that 
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achieve a complete axillary response and the 
group of patients that did not, and determination 
of differences in locoregional and distant recur-
rence rates among a group of all ypn0 patients 
and the group of all not-ypn0 patients.
RESULTS
from May 2016 till May 2018, 95 breast can-
cer patients underwent nast, followed by sur-
gery in cHc rijeka. We excluded 30 patients from 
the analysis, for a history of metastatic disease, 
inflammatory, bilateral, and T4 stages of breast 
cancer. the remaining 65 patients were divided 
into four groups.
(proportion difference test, p=0.79) between them 
regardless of the extent of surgical procedure 
(slnB vs. alnD).
However, statistically, significantly lower pre­
valence of distant recurrence was observed in 
ypn0 group of patients compared to a group of 
patients that did not achieve complete pathologic 
axillary remission following nast (proportion 
difference test, p=0.042), and the prevalence of lo-
cal relapse was at the borderline of the statistical 
significance (proportion difference test, p=0.057).
Table 1.
Display all relevant data for the present retrospective analysis
Group 1 Group 2 Group 3 Group 4







Number of patients 13 22 4 26 
SLNB (N) 11 9 4 (+) 0
ALND (N) 2 13 4 26 
Regional Recurrence 
(N) 0 0 0 0
Local Recurrence (N) 0 0 0 3 
Distant Recurrence 
(N) 0 2 0 7 
cn=clinical status of axillary lymph nodes before nast
ypn=pathological status of axillary lymph nodes after nast
from 65 patients, 17 patients (26.15%) had 
clinically negative axilla at the time of diagnosis 
(groups 1 and 3), and 48 patients (73.85%) had 
clinically positive axilla (group 2 and 4).
twenty-three patients had surgery before 
May 2017 and the rest of 42 patients after that date. 
Hence, we recorded an increasing trend of nast 
for operable tumors (82.6% in one year).
following nast, we recorded the complete 
pathologic axillary remission (ypn0(sn) and ypn0) 
in 22 patients (group 2) from those with initially 
involved axilla (45.83%). In the first postoperative 
year, we did not record regional or local recur-
rence in group 2 patients, and there was no statis-
tically significant difference in distant recurrence 
Figure 1. Differences in distant recurrence rate and local recur­
rence rate between ypN­ (ypN0) patients and ypN+ (ypN1­3) 
patients in the first postoperative year
Figure 2. Progression­free survival curves between patients who 
shift to ypN0 by NAST and patients who remain node­positive 
after NAST.
although progression-free survival rates (cal-
culated by the method of Kaplan Meier) were 
90.91% for group 2 and 69.23% for group 4, com-
parison of progression-free survival curves (fig-
ure 2) did not reach statistical significance in 
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merely one year of follow up period (log-rank 
test, p=0.086).
as expected, more complications were relat-
ed to the extensiveness of the surgical procedure. 
recorded rates of seroma and lymphoedema cor-
related to the extent of axillary surgery, as shown 
in figure 3.
ences of pfs rates, observed among patients with 
complete axillary response to neoadjuvant treat-
ment and patients that did not achieve complete 
axillary remission, imply that node status after 
nast is far more relevant prognostic factor than 
node status at the beginning of treatment. We 
strongly believe that with the larger sample size 
and the more extended postoperative follow-up 
period, these differences would overcome border-
line significance and become statistically signifi-
cant.
Upon the idea of utilization slnB within ax-
illary surgery for early breast cancer in 1994 (4,5) 
through the implementation of the method in clin-
ical practice in 2003 in cHc rijeka, the indications 
for slnB are extended far beyond axillary man-
agement of early breast cancer. they have become 
a method of choice for the axillary approach in the 
majority of breast cancer patients after nast, who 
achieve complete clinically axillary remission.
Year after year, we witness an increasing 
trend of nast application for operable breast 
cancer to reduce the extent of surgery, improve 
the quality of life by reducing the complications 
rate of lymphoedema and seroma. Because 45% of 
patients with initially positive axillary lymph 
node(s) shift to pathologically negative after nast, 
alnD has become overtreatment for those pa-
tients. standardization of the method improved 
an initially wide range of identification rates and 
false-negative results. the biopsy of at least three 
sentinel nodes, marking positive node before 
nast and biopsy of a marked node during the 
surgical procedure, preoperative ultrasound axil-
lary reevaluation, using dual tracer and using the 
iHc for detecting metastasis in nodes) (19,20,21) 
introduced SLNB in practice even in this setting. 
After consensus in St. Gallen (22) and modifica-
tion of nccn guidelines in 2017 (23), slnB after 
nast we also introduced in cHc rijeka. in the 
beginning, we did not use a dual tracer. We did 
not mark and biopsy initially positive nodes ei-
ther, our observations and first clinical experienc-
es indicate that slnB is not inferior to alnD in 
this setting for maintaining both locoregional and 
overall control of disease in initially node-positive 
patients that achieved complete clinical axillary 
remission following nast.
limitations of this study are a relatively small 
group of patients, short postoperative follow-up 
period, and inconsistency of initial cytology proof 
Figure 3. Differences in early and late postoperative complica­
tions in correlation with the extent of axillary surgery
DISCUSSION
We presented our initial experience with 
slnB after nast in initially node-positive breast 
cancer patients. in 48 patients with initially in-
volved axilla, we had no regional recurrence in the 
first postoperative year and only 3 cases of local 
recurrences. in patients that did not achieve path-
ological complete axillary remission, we perfor-
med alnD. in patients with ypn0 stage, no lo-
coregional recurrence and no significant differ-
ence in the prevalence of the distant recurrence, 
regardless of the extent of surgical procedure 
(slnB vs. alnD), suggests that slnB is an ade-
quate alternative to alnD for this group of pa-
tients. our results are in concordance with the 
previously published italian retrospective analy-
sis (18) on 147 initially cn1-2 patients converted to 
cn0, i.e., 70 sentinels node-negative and 77 senti-
nels node-positive. all sentinel node-positive pa-
tients had alnD. in 5 years, follow up a statisti-
cally significant difference in locoregional recur-
rence was not found between slnB and alnD 
group.
Borderline significant differences for local re-
lapse and distant recurrence, as well as the differ-
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for metastasis in nodes that we classified as posi-
tive. Based on these preliminary findings, we initi-
ated a prospective trial in september 2018. (pro-
tocol is available at www.clinicaltrials.gov. iD: 
nct03719833).
CONCLUSION
analysis of one year follow up results of 
breast cancer patients operated after neoadjuvant 
systemic therapy in cHc rijeka from May 2016 
until May 2018 showed a significant increasing 
trend of nast for operable but locally advanced 
breast cancer.
in our group of 65 patients, 73.85 % had posi-
tive axillary nodes at the time of diagnosis, and 
45.83% achieved complete clinical axillary remis-
sion (ypn0/ypn0(sn)).
Observed clinical outcomes in the first post-
operative year suggest that slnB after nast is a 
reliable approach, not inferior to alnD for locore-
gional and overall control of the disease. further-
more, lymph node status after nast is a more 
influential prognostic factor than lymph node sta-
tus at the beginning of treatment.
Herein we want to point out that by multidis-
ciplinary, individual approach to every patient 
after nast and appropriate axillary reevaluation, 
we probably can omit alnD with its consecutive 
morbidity in the selected group of patients (in our 
trial for 45% of initially node-positive patients) 
without compromising oncologic principles and 
without negative impact on clinical outcome. 
These were preliminary findings and an ongoing 
prospective trial designed to test these results in a 
large group of patients (24).
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UTJECAJ BIOPSIJE SENTINEL LIMFNOG ČVORA  
NAKON NEOADJUVANTNOG SISTEMSKOG LIJEČENJA NA KLINIČKI ISHOD BOLESNICA  
OBOLJELIH OD KARCINOMA DOJKE SA INICIJALNO POZITIVNOM AKSILOM
A. Car Peterko, M. Avirović, P. Valković Zujić, I. Belac Lovasić and F. Lovasić
Uvod: Nakon konsenzusa postignutog na konferenciji u St. Gallen­u i revizije NCCN­ovih smjernica za liječenje kar-
cinoma dojke, u svibnju 2017. godine u Kliničkom Bolničkom Centru Rijeka, biopsija sentinel limfnog čvora uvedena je u 
kliničku praksu kirurškog liječenja bolesnica oboljelih od karcinoma dojke koje su neoadjuvantnim liječenjem postigle kli-
ničku remisiju u aksili. Primarni cilj ovog istraživanja bila je evaluacija kliničkog utjecaja metode u gore navedenoj skupini 
pacijentica.
Metode: U ovu retrospektivnu analizu uključene su sve bolesnice oboljele od karcinoma dojke, liječene u KBC Rijeka 
u period od svibnja 2016. do svibnja 2018., kod kojih je preoperativno provedeno sistemsko onkološko liječenje. U prvoj 
postoperativnoj godini praćena je pojava lokoregionalnog i sistemskog recidiva.
Rezultati: Četrdeset i osam od sveukupno 65 bolesnica uključenih u analizu prezentiralo se je sa pozitivnim aksilarnim 
limfnim čvorovima u vrijeme postavljanja dijagnoze, od kojih je 45.83% postiglo kompletnu patološku aksilarnu remisiju. 
Kod ove skupine pacijentica u prvoj postoperativnoj godini nije zabilježen niti jedan slučaj lokoregionalnog recidiva, niti 
statistički značajna razlika u pojavnosti udaljenih metastaza u korelaciji sa opsegom kirurškog zahvata u aksili. Međutim, u 
komparaciji sa ovom skupinom, kod bolesnica koje nisu postigle kompletnu aksilarnu remisiju zabilježene su više stope i 
lokoregionalnog i distalnog recidiva. Zaključak: Biopsija sentinel limfnog čvora je pouzdana alternativa aksilarnoj disekciji 
za postizanje lokoregionalne kontrole i kontrole bolesti uopće, kod bolesnica oboljelih od karcinoma dojke koje neoadju­
vantnim sistemskim liječenjem postignu kompletnu kliničku aksilarnu remisiju. Odgovor aksilarnih limfnih čvorova na 
neoadjuvantno liječenje važniji je prognostički čimbenik od statusa limfnih čvorova na početku liječenja.
KLJUČNE RIJEČI: biopsija limfnog čvora čuvara, neoadjuvantna terapija, recidiv
